Effects of tolterodine on early irritative complication of lower urinary tract after transurethral resection of prostate

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112255786N3

Enrollment

Registered

2012-08-06

Start date

2012-03-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia. N40

Interventions

Intervention 1: tolteroadin 2mg ,oral tablet, 2 times daily. Intervention 2: placebo, oral tablet, twice daily.

Treatment - Drugs

Placebo

tolteroadin 2mg ,oral tablet, 2 times daily

placebo, oral tablet, twice daily

Eligibility

Sex/Gender

Male

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: all patients that hospitalized for TURP in Feb to june in urmia imam khomeini hospital Exclusion criteria: patients withbladder diverticula; neurologic disease; cardiovascular disease; hypo and hyperthyroidisim and patients with history of using cholinergic and antichonergic drugs, post-voding residue more than 70 ml

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lower urinary tract symptoms. Timepoint: Before and one month after intervention. Method of measurement: Questionnaire.;Analgesic nomber after surgery. Timepoint: 1 month. Method of measurement: nomber of analgesic.;Quality of life (IPSS). Timepoint: 1 month. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Urinary retension. Timepoint: 1 month. Method of measurement: Questionnairy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Tehranchi

Urmia university of medical sciences

tehranchi_a@umsu.ac.ir;Drtehranchi@yahoo.com+98 44 1346 9931

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026